莱茵生物(002166) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 reached ¥341,215,308.03, representing a 35.07% increase compared to ¥252,624,843.19 in the same period last year[3] - Net profit attributable to shareholders was ¥26,790,064.13, up 34.37% from ¥19,937,378.89 year-on-year[3] - The net profit after deducting non-recurring gains and losses surged by 372.05% to ¥39,570,887.50, compared to ¥8,382,853.49 in the previous year[3] - The company achieved a consolidated revenue of RMB 341.22 million in Q1 2024, representing a year-on-year growth of 35.07%[15] - The net profit attributable to shareholders reached RMB 26.79 million, a year-on-year increase of 34.37%, with a 372.05% growth in net profit after deducting non-recurring gains and losses[15] - In Q1 2024, the company reported a net profit of CNY 27,884,546.77, an increase of 22.8% compared to CNY 22,746,832.35 in Q1 2023[30] - The total revenue from operating activities reached CNY 665,699,925.37, up from CNY 392,343,449.64 in the same period last year, representing a growth of 69.5%[32] - The company's operating profit was CNY 38,694,563.32, compared to CNY 26,222,155.48 in Q1 2023, marking a year-over-year increase of 47.6%[30] - The total comprehensive income for the period was CNY 29,338,961.00, compared to CNY 13,309,904.98 in the same quarter last year, reflecting a growth of 120.5%[31] - The company reported a significant increase in sales revenue from CNY 627,894,881.41 in Q1 2024, compared to CNY 359,879,120.69 in Q1 2023, indicating a growth of 74.5%[32] Cash Flow and Assets - The net cash flow from operating activities increased significantly to ¥15,776,635.33, a 2,956.62% rise from -¥552,283.38 in Q1 2023[3] - The company's cash and cash equivalents increased by 67.16% to ¥218,063,579.63, driven by a substantial rise in sales collections[8] - The company's cash and cash equivalents increased to RMB 218,063,579.63 from RMB 130,453,809.30, reflecting a growth of approximately 67%[25] - The cash flow from operating activities showed a net increase of CNY 15,776,635.33, contrasting with a negative cash flow of CNY -552,283.38 in Q1 2023[32] - The cash and cash equivalents at the end of the period amounted to CNY 110,892,028.16, a slight increase from CNY 110,718,019.51 at the beginning of the period[33] Shareholder Information - As of March 31, 2024, the company repurchased a total of 7,992,071 shares, accounting for 1.08% of the total share capital, with a total transaction amount of RMB 49.96 million[18] - The company plans to use between RMB 100 million and RMB 200 million for share repurchase to enhance investor confidence[17] - The company has implemented a share repurchase plan to support employee stock ownership and incentive programs[17] - The major shareholders include Qin Benjun with a 36.58% stake, and the top ten shareholders hold a significant portion of the company's shares[14] Investments and Agreements - The company signed a new five-year agreement with DSM-Firmenich, with a total contract value of USD 68 million, of which USD 1.41 million has been fulfilled in the current reporting period[19][20] - The company is investing USD 5 million to establish two brand and operation companies in the U.S. for industrial hemp vaporization products, with operations officially commenced[21][22] Operational Metrics - Total assets at the end of Q1 2024 were ¥4,768,230,024.88, reflecting a 3.08% increase from ¥4,625,577,132.96 at the end of the previous year[3] - The company's basic earnings per share rose to ¥0.04, a 33.33% increase from ¥0.03 in the same quarter last year[3] - The weighted average return on equity improved to 0.86%, up from 0.65% year-on-year[3] - The total operating costs for the first quarter of 2024 were RMB 297,588,999.84, up from RMB 241,217,950.90 in the previous year, indicating a 23.5% increase[29] - The inventory balance rose to RMB 1,250,243,019.00, compared to RMB 971,298,948.11 at the beginning of the period, marking a 29% increase[26] - The total liabilities increased to RMB 1,582,572,457.44 from RMB 1,421,120,433.26, showing a growth of approximately 11.4%[27] - The company's equity attributable to shareholders decreased slightly to RMB 3,111,765,600.41 from RMB 3,131,659,215.31[27] - The company incurred financial expenses of CNY 3,459,863.60, down from CNY 4,099,796.18, a decrease of 15.7%[30] - Research and development expenses decreased to CNY 9,659,639.15 from CNY 11,642,233.61, a reduction of 17.0%[30] Fundraising - The company raised a total of RMB 967,999,997.25 from a private placement of 165,470,085 shares at RMB 5.85 per share, with a net amount of RMB 961,109,931.12 after deducting issuance costs[23] - The company has RMB 48,231.42 million of unutilized raised funds, with RMB 48,000.00 million temporarily used to supplement working capital[23] - The company reported cumulative interest income from the raised funds amounting to RMB 14,765,200.00[23]